Henlius doses first patient in HLX43 combination trial
Shanghai Henlius Biotech, Inc. (HKEX:2696) announced that the first patient has been dosed in a Phase 1b/2 clinical trial of HLX43, an antibody-drug conjugate targeting PD-L1, in combination with HANSIZHUANG (serplulimab injection) for the treatment of patients with advanced/metastatic solid tumours. The trial is designed to evaluate the safety, tolerability, and efficacy of the combination therapy. The study will proceed in two stages: an initial dose-escalation phase, followed by a dose-expansion phase. HLX43, developed by Henlius with licensed technology from MediLink Therapeutics, targets PD-L1. HANSIZHUANG is Henlius's independently developed anti-PD-1 monoclonal antibody, already approved for marketing in mainland China and the EU for several indications. The company has also initiated phase 2 clinical trials of HLX43 in potential solid tumours indications including esophageal squamous cell carcinoma (ESCC).
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Shanghai Henlius Biotech, Inc publishes news
Free account required • Unsubscribe anytime